
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/">
  <dc:description xml:lang="eng">Abstract: Background. Some drugs developed for other illnesses might be repurposed for cancer treatment, to kill cancer cells by hitting previously recognized or unrecognized molecular target or unknown target. This study investigated such drugs, with proven in vitro anticancer effects, in vivo on fibrosarcoma in hamsters. Material and Methods. Anticancer efficacy of selected repurposed drugs: mebendazole, metformin, diclofenac, 2-Deoxy-D-glucose, deoxycholic acid, caffeine, itraconazole, nitroglycerin, disulfiram and selected two-component combinations were tested on fibrosarcoma experimentally induced by 
BHK-21/C13 cells in Syrian golden hamsters. Tumor biophysical characteristics, histology and immunohistochemistry were assessed. Blood samples were collected for hematological and biochemical analyses and the main organs were toxicologically analyzed. Results. This study showed that two-drug combinations: metformin with 2-Deoxy-D-glucose, metformin with deoxycholic acid, metformin with caffeine, metformin with itraconazole, metformin with nitroglycerin and metformin with disulfiram can significantly (P &lt; 0.05) suppress fibrosarcoma in hamsters with doses equivalent to achievable oncological human doses, without toxicity and influence on biochemical and hematological tests. Conclusion. All efficacious repurposed drug combinations recorded in our study on hamster fibrosarcoma can be recommended for further clinical trials.
</dc:description>
  <dc:date>2023</dc:date>
  <dc:subject xml:lang="eng">Keywords : BHK-21/C13, cell culture, drug combinations, drug effects, fibrosarcoma, hamsters</dc:subject>
  <dc:format>application/pdf</dc:format>
  <dc:format>1398244 bytes</dc:format>
  <dc:title xml:lang="eng">Anticancer effects of non-toxic repurposed drugs on hamster fibrosarcoma – fast applicable in oncology</dc:title>
  <dc:identifier>https://phaidrabg.bg.ac.rs/o:31386</dc:identifier>
  <dc:identifier>ISSN: 3009-3848</dc:identifier>
  <dc:source>Proceedings Book of the 6th Congress of the Serbian Association for Cancer Research – SDIR with international participation “From Collaboration to Innovation in Cancer Research”, October 2-4 2023, Belgrade, Serbia. Official Journal of the Serbian Association for Cancer Research Oncology Insights, October 2023;1(1): 94-95 (P38)  1(1)</dc:source>
  <dc:language>eng</dc:language>
  <dc:creator id="https://orcid.org/0000-0001-7880-0874">Popović J., Dušica</dc:creator>
  <dc:creator id="https://orcid.org/0000-0001-7895-9009">Popović J., Kosta</dc:creator>
  <dc:creator id="https://orcid.org/0000-0002-7739-5202">Miljković, Dejan</dc:creator>
  <dc:creator id="https://orcid.org/0000-0002-0760-9180">Lalošević, Dušan</dc:creator>
  <dc:creator id="https://orcid.org/0000-0003-0457-3087 https://plus.cobiss.net/cobiss/sr/sr/conor/2237799">Dolićanin, Zana</dc:creator>
  <dc:creator id="https://orcid.org/0000-0001-7531-5099">Čapo, Ivan</dc:creator>
  <dc:creator id="https://orcid.org/0000-0002-6790-8668">Popović K., Jovan</dc:creator>
  <dc:rights>All rights reserved</dc:rights>
  <dc:type>info:eu-repo/semantics/conferenceProceedings</dc:type>
</oai_dc:dc>